{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:33:32Z","timestamp":1763141612014,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40618-021-01642-0","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T19:02:26Z","timestamp":1626721346000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-3366","authenticated-orcid":false,"given":"A.","family":"Laffi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"5","key":"1642_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","volume":"39","author":"O Basturk","year":"2015","unstructured":"Basturk O, Yang Z, Tang Lh, Hruban Rh, Adsay V, Cm M et al (2015) The High-grade (who g3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39(5):683\u2013690","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1642_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/ERC-15-0119","volume":"22","author":"M Heetfeld","year":"2015","unstructured":"Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G et al (2015) Characteristics and treatment of patients with g3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 22(4):657\u2013664","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"1642_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1530\/ERC-13-0027","volume":"20","author":"Fl Velayoudom-Cephise","year":"2013","unstructured":"Velayoudom-Cephise Fl, Duvillard P, Foucan L, Hadoux J, Chougnet Cn, Leboulleux S et al (2013) Are G3 enets neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer. 20(5):649\u2013657","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"1642_CR4","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (who g3): the nordic nec study. Ann Oncol. 24(1):152\u2013160","journal-title":"Ann Oncol."},{"issue":"1","key":"1642_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000445165","volume":"104","author":"M Milione","year":"2017","unstructured":"Milione M, Maisonneuve P, Spada F, Pellegrinelli A, Spaggiari P, Albarello L et al (2017) The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104(1):85\u201393","journal-title":"Neuroendocrinology"},{"key":"1642_CR6","volume-title":"Who classification of tumours of endocrine organs (World Health Organization Classification Of Tumors)","author":"LR Or","year":"2017","unstructured":"Or LR, Kloppel G, Rosai J et al (2017) Who classification of tumours of endocrine organs (World Health Organization Classification Of Tumors), 4th edn. Iarc Press, Lyons France","edition":"4"},{"key":"1642_CR7","volume-title":"Who classification of tumor editorial board; digestive system tumours, who classification of tumours","author":"NI Or","year":"2019","unstructured":"Or NI, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington M, Carneiro F, Cree I (2019) Who classification of tumor editorial board; digestive system tumours, who classification of tumours, 5th edn. Iarc Press, France","edition":"5"},{"issue":"4","key":"1642_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/modpathol.2016.217","volume":"30","author":"B Konukiewitz","year":"2017","unstructured":"Konukiewitz B, Am S, Jesinghaus M, Pfister D, Steiger K, Segler A et al (2017) Somatostatin receptor expression related to Tp53 and Rb1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with A Ki67-index above 20. Mod Pathol 30(4):587\u2013598","journal-title":"Mod Pathol"},{"issue":"2","key":"1642_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","volume":"36","author":"S Yachida","year":"2012","unstructured":"Yachida S, Vakiani E, Cm W, Zhong Y, Saunders T, Morgan R et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36(2):173\u2013184","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1642_CR10","first-page":"255","volume":"1826","author":"S Dr","year":"2012","unstructured":"Dr S, Fc R, Ej S (2012) Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 1826(2):255\u2013271","journal-title":"Biochim Biophys Acta"},{"issue":"19","key":"1642_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/jnci\/89.19.1448","volume":"89","author":"V Ao","year":"1997","unstructured":"Ao V, Ia L, Mj M, Cy W, Pham T, Ee F et al (1997) Concordance of genetic alterations in poorly differentiated colorectal neuroendocrine carcinomas and associated adenocarcinomas. J Natl Cancer Inst 89(19):1448\u20131453","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1642_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00292-019-0594-3","volume":"40","author":"G Kloppel","year":"2019","unstructured":"Kloppel G (2019) Neuroendocrine neoplasms: two families with distinct features unified in one classification (German version). Pathologe 40(3):211\u2013219","journal-title":"Pathologe"},{"key":"1642_CR13","volume-title":"Tnm classification of malignant tumours","author":"BJ Gm","year":"2016","unstructured":"Gm BJ, Wittekind C (2016) Tnm classification of malignant tumours, 8th edn. Wiley","edition":"8"},{"issue":"10","key":"1642_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/RLU.0000000000002694","volume":"44","author":"L Dy","year":"2019","unstructured":"Dy L, Yi K (2019) Prognostic value of maximum standardized uptake value in 68ga-somatostatin receptor positron emission tomography for neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med 44(10):777\u2013783","journal-title":"Clin Nucl Med"},{"key":"1642_CR15","first-page":"2340389","volume":"2018","author":"P Zhang","year":"2018","unstructured":"Zhang P, Yu J, Li J, Shen L, Li N, Zhu H et al (2018) Clinical and prognostic value of pet\/ct imaging with combination of (68)Ga-Dotatate and (18)F-Fdg in gastroenteropancreatic neuroendocrine neoplasms. Contrast Media Mol Imaging 2018:2340389","journal-title":"Contrast Media Mol Imaging"},{"issue":"6","key":"1642_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.18632\/oncotarget.27460","volume":"11","author":"I Karfis","year":"2020","unstructured":"Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G et al (2020) Prognostic value of a three-scale grading system based on combining molecular imaging with (68)ga-dotatate and (18)f-fdg pet\/ct in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias. Oncotarget 11(6):589\u2013599","journal-title":"Oncotarget"},{"issue":"2","key":"1642_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B et al (2017) Phase 3 trial of (177)lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376(2):125\u2013135","journal-title":"N Engl J Med"},{"issue":"6","key":"1642_CR18","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00259-013-2369-z","volume":"40","author":"S Severi","year":"2013","unstructured":"Severi S, Nanni O, Bodei L, Sansovini M, Ianniello A, Nicoletti S et al (2013) Role of 18fdg pet\/ct in patients treated with 177lu-Dotatate for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40(6):881\u2013888","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1642_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","volume":"16","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A (2010) 18f-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 16(3):978\u2013985","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1642_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000493318","volume":"108","author":"H Sorbye","year":"2019","unstructured":"Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB et al (2019) Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (Who G3). Neuroendocrinology 108(1):54\u201362","journal-title":"Neuroendocrinology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01642-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01642-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T10:21:22Z","timestamp":1642846882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01642-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01642-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"type":"electronic","value":"1720-8386"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective analysis complies with the Declaration of Helsinki and was approved by our local internal review board (IRB), and the IEO Data Protection Officer, with the U-ID of 2259.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The retrospective analysis complies with the Declaration of Helsinki and was approved by our local internal review board (IRB), and the European Institute of Oncology Data Protection Officer, with the U-ID of 2259.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"As a retrospective study, a specific informed consent was not needed and all collected data were anonymized. Every patient gave the consent for the research, as required by the Institution regulation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}